Advertisement

Topics

EMA grants marketing not for GSK's self─injectable formulation of Benlysta to treat systemic lupus erythematosus

08:03 EST 15 Nov 2017 | PharmaBiz

GSK has announced that the European Commission has approved a new subcutaneous (SC) formulation of Benlysta (belimumab), as an add─on therapy in adult patients with active autoantibody─positive systemic lupus erythematosus

Original Article: EMA grants marketing not for GSK's self─injectable formulation of Benlysta to treat systemic lupus erythematosus

NEXT ARTICLE

More From BioPortfolio on "EMA grants marketing not for GSK's self─injectable formulation of Benlysta to treat systemic lupus erythematosus"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

Rheumatology
Arthritis Fibromyalgia Gout Lupus Rheumatic Rheumatology is the medical specialty concerned with the diagnosis and management of disease involving joints, tendons, muscles, ligaments and associated structures (Oxford Medical Diction...